Lineage Cell Therapeutics, Inc.

For the period ended Jun 30, 2025. Filed Aug 12, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2025 · Filed Aug 12, 2025

LCTX$1.08+5.9%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Changes in Shareholders' Equity

Three Months Ended June 30, 2025
Accumulated
Other · Total
Common Shares · Accumulated · Noncontrolling · Comprehensive · Shareholders’
	Shares	Amount	Deficit	Deficit	Income / (Loss)	Equity
BALANCE - March 31, 2025	228,356	$489,313	$(407,604)	$(1,373)	$(2,681)	$77,655
Stock-based compensation	—	1,238	—	—	—	1,238
Foreign currency translation adjustment	—	—	—	—	(1,417)	(1,417)
Net income (loss)	—	—	(30,464)	100	—	(30,364)
BALANCE - June 30, 2025	228,356	$490,551	$(438,068)	$(1,273)	$(4,098)	$47,112

Three Months Ended June 30, 2024
Accumulated
Other · Total
Common Shares · Accumulated · Noncontrolling · Comprehensive · Shareholders’
	Shares	Amount	Deficit	Deficit	Income / (Loss)	Equity
BALANCE - March 31, 2024	188,754	$466,571	$(391,398)	$(1,412)	$(2,771)	$70,990
Shares issued through ATM financing	26	33	—	—	—	33
Financing related fees	—	(1)	—	—	—	(1)
Shares issued upon exercise of stock options	44	56	—	—	—	56
Stock-based compensation	—	1,269	—	—	—	1,269
Unrealized loss on marketable debt securities	—	—	—	—	(6)	(6)
Foreign currency translation adjustment	—	—	—	—	307	307
Net loss	—	—	(5,760)	(13)	—	(5,773)
BALANCE - June 30, 2024	188,824	$467,928	$(397,158)	$(1,425)	$(2,470)	$66,875

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS’ EQUITY

Six Months Ended June 30, 2025
Accumulated
Other · Total
Common Shares · Accumulated · Noncontrolling · Comprehensive · Shareholders’
	Shares	Amount	Deficit	Deficit	Income / (Loss)	Equity
BALANCE - December 31, 2024	220,416	$484,722	$(403,465)	$(1,369)	$(2,876)	$77,012
Shares issued through registered direct financing	7,895	3,795	—	—	—	3,795
Financing related fees	—	(406)	—	—	—	(406)
Shares issued upon vesting of restricted stock units, net of shares retired to pay employees’ taxes	45	(15)	—	—	—	(15)
Stock-based compensation	—	2,455	—	—	—	2,455
Unrealized loss on marketable debt securities	—	—	—	—	(5)	(5)
Foreign currency translation adjustment	—	—	—	—	(1,217)	(1,217)
Net income (loss)	—	—	(34,603)	96	—	(34,507)
BALANCE - June 30, 2025	228,356	$490,551	$(438,068)	$(1,273)	$(4,098)	$47,112

Six Months Ended June 30, 2024
Accumulated
Other · Total
Common Shares · Accumulated · Noncontrolling · Comprehensive · Shareholders’
	Shares	Amount	Deficit	Deficit	Income / (Loss)	Equity
BALANCE - December 31, 2023	174,987	$451,343	$(384,856)	$(1,396)	$(3,068)	$62,023
Shares issued through registered direct financings	13,462	14,000	—	—	—	14,000
Shares issued through ATM financing	56	70	—	—	—	70
Financing related fees	—	(113)	—	—	—	(113)
Shares issued upon vesting of restricted stock units, net of shares retired to pay employees’ taxes	45	(23)	—	—	—	(23)
Shares issued upon exercise of stock options	274	219	—	—	—	219
Stock-based compensation	—	2,432	—	—	—	2,432
Unrealized loss on marketable debt securities	—	—	—	—	(7)	(7)
Foreign currency translation adjustment	—	—	—	—	605	605
Net loss	—	—	(12,302)	(29)	—	(12,331)
BALANCE - June 30, 2024	188,824	$467,928	$(397,158)	$(1,425)	$(2,470)	$66,875

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.